Metal Producer Secures Impressive Gold-Silver Assets Across Americas. Analyst Sees Extraordinary 94% Upside
Research Report
US Oil & Gas Co. Posts Strong Q1/25
Research Report
Analyst Reveals Undervalued Pharmaceutical Gem in Canada
Research Report
Steel Firm Secures Sports Complex Renovation in Western USA Despite Trade Headwinds
Research Report
Four-Year Data on New Drug for Early AD Positive
Research Report
Cleantech, Life Sciences Co. Has Multiple Shots on Goal
Research Report
Rest of 2025 Rich With Catalysts for Immunotherapy Co.
Research Report
New Drug for Early AD Shown to be Efficacious, Safe
Research Report
Trial participants exhibited improvements in cognitive function and activities of daily living, noted a D. Boral Capital report. New Therapy for AATD Could be Best in Class
Research Report
Updated trial data show it to be safe and efficacious and have a dual mechanism of action, noted an H.C. Wainwright & Co. report. Share Price Appreciation of Biotech Due Over Next Six Months
Research Report
Given its robust pipeline, numerous milestones for this Outperform-rated company are slated to occur in the near-term, noted a Wedbush report. Biotech Co. Has Promising AI-Accelerated Pipeline
Research Report
Rakovina Therapeutics Inc. (RKV:TSX.V) recently gained analyst coverage from First Berlin Equity Research. Read on to see why this company rates the stock a Buy. Gold, Silver Names Buoy Coverage Universe in Q1/25
Research Report
The share price of three companies in the group rose more than 65% during this period, Atrium Research noted in a research report. Ascending Dose Trial of FABP5 Inhibitor to Read Out Soon
Research Report
Meanwhile, a representative from the company advancing the small molecule in the clinic is slated to speak about it at a conference this week, noted a D. Boral Capital report. Cell Pouch Co. Peer Aborts Program Using Like Device
Research Report
The implications for Cell Pouch, an implantable cell delivery vehicle, and the biotech behind it are positive, noted a Leede Financial Inc. report. New Jersey Pharma Co. Shares Positive Pediatric Study
Research Report
Aquestive Therapeutics Inc. (AQST:NASDAQ) recently reported that it completed New Drug Application (NDA) submission for Anaphylm and positive pediatric study data for the non-device-based epinephrine product candidate, noted an H.C. Wainwright & Co. research note. Smart Building Co. Has Significant Upside Potential, Analyst Says
Research Report
One Atrium Research analyst believes that Kontrol Technologies Corp. (KNR:CBOE.CA; KNRLF:OTCQB; 1K8:FSE) is a Buy. Read on to see why. 
Streetwise Key Charts
